How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.
Yonatan S. Resnick, PharmD
Advertisement
Articles by Yonatan S. Resnick, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Boston Panel Confronts Access and Coordination Gaps in Obesity Care
5